Pyxis Oncology (NASDAQ:PYXS) Releases Earnings Results, Beats Expectations By $0.03 EPS

Pyxis Oncology (NASDAQ:PYXS) issued its quarterly earnings results on Thursday. The company reported ($0.24) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.03, FiscalAI reports.

Pyxis Oncology Stock Up 4.7%

Shares of Pyxis Oncology stock traded up $0.07 on Friday, reaching $1.69. 119,175 shares of the stock were exchanged, compared to its average volume of 903,678. Pyxis Oncology has a twelve month low of $1.03 and a twelve month high of $5.55. The firm has a market capitalization of $140.54 million, a price-to-earnings ratio of -1.20 and a beta of 1.41. The business has a 50 day moving average price of $2.54 and a two-hundred day moving average price of $2.16.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. HC Wainwright lifted their target price on shares of Pyxis Oncology from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Stifel Nicolaus set a $5.00 price target on shares of Pyxis Oncology in a research note on Thursday. Wedbush raised their price target on shares of Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Pyxis Oncology in a research note on Friday, September 25th. Finally, Wells Fargo & Company boosted their price objective on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $8.57.

About Pyxis Oncology

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.